Catherine Coste - 20 Nov 2023 Form 4 Insider Report for Renalytix plc (RNLX)

Role
Director
Signature
/s/ Katie Kazem, Attorney-in-Fact
Issuer symbol
RNLX
Transactions as of
20 Nov 2023
Transactions value $
$0
Form type
4
Filing time
22 Nov 2023, 16:29:33 UTC
Previous filing
07 Jul 2023
Next filing
11 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNLX Employee Stock Option (right to buy) Award $0 +95,000 $0 95,000 20 Nov 2023 Ordinary Shares 95,000 $0.304 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).
F2 One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service.